New study monitors psoriasis drug safety in pregnant women
NCT ID NCT03992729
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 pregnant women who take tildrakizumab for conditions like psoriasis, along with a similar group who don't take the drug. Researchers track pregnancy outcomes and infant health up to one year after birth to check for birth defects or other problems. The goal is to gather safety information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Christina Chambers
RECRUITINGSan Diego, California, 92093, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antimalarials be safely used in early pregnancy? a massive registry seeks answers
- Texts and local mentors: a new way to empower teen girls on contraception?
- Mindfulness during pregnancy: a new way to boost mental health and baby bonding?
- Teaching Moms-to-Be about seafood safety: a new weapon against toxic exposures?
- Can we improve emergency C-Sections for the sickest mothers?
- Can DIY insulin algorithms match commercial systems for pregnant women with type 1 diabetes?